ClinicalTrials.Veeva

Menu
L

Lakes Research | Miami Lakes, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Pegcetacoplan
Baricitinib
Docetaxel
Abemaciclib
Cyclophosphamide
Pegfilgrastim
APL-2
Azacitidine
Mocetinostat
LY3009104

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 31 total trials

A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (MONARCH 3)

The main purpose of this study is to evaluate how effective nonsteroidal aromatase inhibitors (NSAI) plus abemaciclib are in postmenopausal women wit...

Active, not recruiting
Breast Cancer
Drug: Letrozole
Drug: Placebo

The phase 3 study is to compare the efficacy and safety of palonosetron, a long-acting 5-HT3 receptor antagonist, by buccal film delivery compared to...

Enrolling
Chemotherapy-induced Nausea and Vomiting
Drug: IV Palonosetron 0.25 mg
Drug: Palonosetron HCl Buccal Film 0.5 mg

The main purpose of this study is to evaluate the efficacy and safety of M281 in participants with warm autoimmune hemolytic anemia (wAIHA).

Enrolling
Warm Autoimmune Hemolytic Anemia
Drug: M281
Drug: Placebo

This study is an open-label, single arm, multicenter, roll-over extension study to characterize long-term safety, tolerability and efficacy of iptaco...

Enrolling
Paroxysmal Nocturnal Hemoglobinuria
Drug: Iptacopan

A Phase 2a Open-Label Preliminary Safety, Efficacy, and Biomarker Study of WP-0512 in Patients with Amyotrophic Lateral Sclerosis (ALS)

Enrolling
Amyotrophic Lateral Sclerosis
Drug: Fasudil (WP-0512)

The aim of the study is to compare progression-free survival (PFS) in previously treated participants with Kirsten rat sarcoma (KRAS) p.G12C mutated...

Active, not recruiting
Colorectal Cancer (CRC)
Drug: Regorafenib
Drug: Panitumumab

Study CKJX839B12302 is a pivotal Phase III trial to evaluate the benefits of inclisiran on major adverse cardiovascular (MACE) events in participants...

Active, not recruiting
Atherosclerotic Cardiovascular Disease
Drug: Placebo
Drug: Inclisiran sodium 300 mg

This study will confirm the ability of Tc 99m tilmanocept imaging to predict clinical response in individuals with RA who are beginning anti-TNFα the...

Active, not recruiting
Rheumatoid Arthritis
Drug: TC99m-tilmanocept

Trial sponsors

A
Lilly logo
Amgen logo
Novartis logo
Spectrum Pharmaceuticals logo
A
American Regent logo
Biogen logo
CSL Behring logo
Janssen (J&J Innovative Medicine) logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems